Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03186066
Other study ID # ESCAPE
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2, 2017
Est. completion date April 8, 2023

Study information

Verified date March 2024
Source Kliniken Ludwigsburg-Bietigheim gGmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Percutaneous endoscopic gastrostomy (PEG) is a method for nutrition delivery for patients with insufficient oral intake. A rare but severe complication of PEG is the Buried Bumper Syndrome (BBS). In BBS the internal fixation device of the PEG migrates along the stoma chanel. The internal fixation disc becomes covered by gastric mucosa, which causes loss of patency, fixation of the PEG and possible leakage around the PEG. BBS can be treated endoscopically by dissecting the overgrowing tissue with endoscopic submucosal dissection (ESD) knifes. A new and alternative approach is the use of the Flamingo device, which is inserted over the PEG and then is used to radially dissect the overgrowing tissue with a cutting wire. In this study both methods, the standard method using an ESD knife and the Flamingo device, are compared in a randomized controlled open-label trial. Primary endpoint is the time needed for PEG removal.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date April 8, 2023
Est. primary completion date September 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Endoscopy proven Buried Bumper Syndrome - PEG or Jet-PEG Exclusion Criteria: - Major Coagulation disorder - Percutaneous endoscopic jejunostomy or use of a ballon fixed device

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Flamingo Device
Endoscopic Treatment of Buried Bumper Syndrome with the Flamingo Device
Procedure:
Standard Therapy
Endoscopic Treatment of Buried Bumper Syndrome with an endoscopic submucosal dissection knife

Locations

Country Name City State
Germany Klinikum Ludwigsburg Ludwigsburg

Sponsors (1)

Lead Sponsor Collaborator
Kliniken Ludwigsburg-Bietigheim gGmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time for Removal of PEG Assessed at day 1 (day of intervention)
Secondary Success rate Assessed at day 1
Secondary Complications Assessed during follow-up for up to ten days